9月2日 - ** United Therapeutics UTHR.O股价在盘前交易中上涨43.88%至438.50美元
** 公司称 (link) 其药物 Tyvaso 在一项后期试验中达到了改善肺功能的主要目标
** 该试验研究了使用雾化Tyvaso吸入溶液治疗特发性肺纤维化--一种影响肺部气囊或肺泡周围组织的疾病
** 公司打算利用该试验和另一项正在进行的研究的数据来支持其将特发性肺纤维化添加到雾化Tyvaso标签适应症中的申请
** 与UTHR合作开发干粉版Tyvaso的MannKind公司MNKD.O股价在收盘前上涨35.95%，至6.24美元。
** 截至收盘，UTHR股价累计下跌13.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.